Farms.com Home   News

Genetic Selection for Disease Resilience Expected to Become Mainstream

The identification of genetic traits that contribute to disease resilience in swine can be expected to become a mainstream approach to protecting pigs from disease. Since 2015 an international team of scientists has been contributing to a natural disease challenge model, established at the CDPQ wean to finish commercial research facilities in Quebec, for evaluating the resilience of swine to disease.
 
Dr. John Harding, a Professor with the Western College of Veterinary Medicine, explains pigs in the facility are exposed to many of the same infections that would be typically found in a commercial swine operation.
 
Clip-Dr. John Harding-Western College of Veterinary Medicine:
 
The key objective is to find indicator traits of resilience that can be measured in high health farms, nucleus or multiplication farms, that will improve disease resilience when those animals move into commercial farms that are less healthy. Diseases are getting more complex; production systems are getting larger.
 
We have vaccines in our arsenal but they're not always 100 percent effective and we don't have vaccines for some very key diseases. We also have this issue of antibiotics becoming less available to us through our judicious use movement. As well we have factors of resistance that are developing associated with use or over use.
 
The selection of genetically resilient pigs is really a valuable tool that we hope will become mainstream at some point in time in the future. We're not there yet but there are certain companies that are starting to use some of the previous findings from PRRS and perhaps Circovirus and incorporating resilience traits into their genetic selection processes. We're thinking that in the future that will continue as we have more results from this natural disease challenge unit.
Source : Farmscape

Trending Video

A new era in biostimulants and bionutritionals

Video: A new era in biostimulants and bionutritionals


In response to the growing need for efficient, effective biosolutions, HGS BioScience continues to expand its footprint in the bionutritional and biostimulant market with the acquisition of NutriAg, Ltd. The Paine Schwartz Partners-backed HGS BioScience is a global leader in humic and fulvic acid products. Toronto-based NutriAg is an innovator in bionutritional technologies with a deep R&D engine. North American growers and retailers will benefit from:

• Solutions across the biostimulant spectrum - including humics, fulvics, bionutritionals, carbohydrate chelation, amino acids, plant and seaweed extracts, and microbial technologies.
• A portfolio and R&D pipeline of science-backed solutions proven to drive crop productivity and farm profitability.
• Actionable nutrient insights and recommendations based on data specific to their farm and cropping goals with the NutriAnalytics platform